The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker

Inhibitors of the mTOR pathway, such as everolimus, are promising compounds to treat patients with renal cell carcinomas (RCCs). However, the precise mechanisms of action are far from clear, and biomarkers predicting the response to mTOR inhibitors are still missing. Here, we provide evidence that i...

Descripción completa

Detalles Bibliográficos
Autores principales: Knoll, Maximilian, Macher-Goeppinger, Stephan, Kopitz, Jürgen, Duensing, Stefan, Pahernik, Sascha, Hohenfellner, Markus, Schirmacher, Peter, Roth, Wilfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808008/
https://www.ncbi.nlm.nih.gov/pubmed/26506236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808008/
https://www.ncbi.nlm.nih.gov/pubmed/26506236

Ejemplares similares